Spectrum Pharmaceuticals, Inc., and its wholly-owned subsidiary Allos Therapeutics, Inc. proudly sponsors the Allos Support for Assisting Patients (ASAP) program, a reimbursement support and patient assistance program designed to help patients and healthcare professionals gain appropriate access to
FOLOTYN® (pralatrexate injection).
Allos Therapeutics, Inc. does not guarantee coverage and/or reimbursement for FOLOTYN (pralatrexate injection). Coverage, coding, and reimbursement policies vary significantly by payer, patient, and setting of care. Actual coverage and reimbursement decisions are made by individual payers following the receipt of claims. Allos strongly recommends verifying coverage, coding, and reimbursement guidelines on a payer and patient-specific basis.
IMPORTANT SAFETY INFORMATION
Warnings and Precautions
Use in Specific Populations